FDA accepts Amgen’s NDA for novel intravenous calcimimetic etelcalcetide
If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously. Amgen executive vice president of research and development Sean Harper said: "We’re pleased that
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.